S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
BREAKING: Tiny biotech successfully treats blindness (Ad)
Things to know about California's new proposed rules for insurance companies
MarketBeat Week in Review – 9/18 - 9/22
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday, 9/22/2023
Closing prices for crude oil, gold and other commodities
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
BREAKING: Tiny biotech successfully treats blindness (Ad)
Things to know about California's new proposed rules for insurance companies
MarketBeat Week in Review – 9/18 - 9/22
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday, 9/22/2023
Closing prices for crude oil, gold and other commodities
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
BREAKING: Tiny biotech successfully treats blindness (Ad)
Things to know about California's new proposed rules for insurance companies
MarketBeat Week in Review – 9/18 - 9/22
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday, 9/22/2023
Closing prices for crude oil, gold and other commodities
S&P 500   4,320.06
DOW   33,963.84
QQQ   357.91
52-week Low Names To Tip The Upside Scale In Your Favor
Buy This Stock for AI Tidal Wave (not NVDA) (Ad)
3 Reasons This Sleeping Giant Is About To Wake Up
KB Home Price Weakness is a Signal to Buy this Cash Machine
BREAKING: Tiny biotech successfully treats blindness (Ad)
Things to know about California's new proposed rules for insurance companies
MarketBeat Week in Review – 9/18 - 9/22
66,000% upside on tiny biotech? (Ad)
How major US stock indexes fared Friday, 9/22/2023
Closing prices for crude oil, gold and other commodities
NASDAQ:ADUS

Addus HomeCare (ADUS) Stock Forecast, Price & News

$85.72
+0.06 (+0.07%)
(As of 09/22/2023 ET)
Compare
Today's Range
$85.66
$86.95
50-Day Range
$82.88
$96.30
52-Week Range
$77.30
$114.99
Volume
56,227 shs
Average Volume
76,969 shs
Market Capitalization
$1.39 billion
P/E Ratio
25.90
Dividend Yield
N/A
Price Target
$110.50

Addus HomeCare MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
28.9% Upside
$110.50 Price Target
Short Interest
Healthy
1.80% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.50
Upright™ Environmental Score
News Sentiment
1.08mentions of Addus HomeCare in the last 14 days
Based on 3 Articles This Week
Insider Trading
Selling Shares
$3.28 M Sold Last Quarter
Proj. Earnings Growth
11.64%
From $3.78 to $4.22 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.98 out of 5 stars

Medical Sector

32nd out of 967 stocks

Home Health Care Services Industry

3rd out of 7 stocks


ADUS stock logo

About Addus HomeCare (NASDAQ:ADUS) Stock

Addus HomeCare Corporation, together with its subsidiaries, provides personal care services to elderly, chronically ill, disabled persons, and individuals who are at risk of hospitalization or institutionalization in the United States. It operates through three segments: Personal Care, Hospice, and Home Health. The Personal Care segment provides non-medical assistance with activities of daily living. This segment offers services that include assistance with bathing, grooming, oral care, feeding and dressing, medication reminders, meal planning and preparation, housekeeping, and transportation services. The Hospice segment provides palliative nursing care, social work, spiritual counseling, homemaker, and bereavement counseling services for people who are terminally ill, as well as related services for their families. The Home Health segment offers skilled nursing and physical, occupational, and speech therapy for the individuals who requires assistance during an illness or after hospitalization. The company's payor clients include federal, state, and local governmental agencies; managed care organizations; commercial insurers; and private individuals. Addus HomeCare Corporation was founded in 1979 and is headquartered in Frisco, Texas.

ADUS Price History

ADUS Stock News Headlines

3 Medical Stocks Generating Buzz Among Investors
Wall Street Buys: 3 'A' Rated Medical Stocks
The single greatest medical breakthrough of all time?
We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.
BREAKING: Tiny biotech successfully treats blindness
There's a tiny biotech in Cambridge that's using a breakthrough technology to treat blindness. This company has already shown success in human trials... And Our research shows that anyone who gets in today could see a 46,751% return.
The Latest Analyst Ratings for Addus HomeCare
Analyst Expectations for Addus HomeCare's Future
Oppenheimer Keeps Their Buy Rating on Addus Homecare (ADUS)
Addus HomeCare (NASDAQ: ADUS)
See More Headlines
Receive ADUS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Addus HomeCare and its competitors with MarketBeat's FREE daily newsletter.

ADUS Company Calendar

Last Earnings
7/31/2023
Today
9/23/2023
Next Earnings (Estimated)
10/30/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Home health care services
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:ADUS
Employees
33,182
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$110.50
High Stock Price Forecast
$118.00
Low Stock Price Forecast
$105.00
Forecasted Upside/Downside
+28.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
4 Analysts

Profitability

Net Income
$46.03 million
Pretax Margin
6.92%

Debt

Sales & Book Value

Annual Sales
$951.12 million
Cash Flow
$4.17 per share
Book Value
$39.33 per share

Miscellaneous

Free Float
15,487,000
Market Cap
$1.39 billion
Optionable
Optionable
Beta
0.86
7 Energy Stocks to Buy and Hold Forever Cover

Do you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.

Get This Free Report

Key Executives

  • Mr. R. Dirk AllisonMr. R. Dirk Allison (Age 67)
    CEO & Chairman
    Comp: $1.81M
  • Mr. W. Bradley BickhamMr. W. Bradley Bickham (Age 60)
    Pres & COO
    Comp: $942.47k
  • Mr. Brian W. PoffMr. Brian W. Poff (Age 49)
    CFO, Exec. VP, Sec. & Treasurer
    Comp: $842.78k
  • Ms. Monica Raines (Age 44)
    Exec. VP and Chief Compliance & Quality Officer
    Comp: $538.17k
  • Mr. Cliff Blessing (Age 43)
    Exec. VP & Chief Devel. Officer
    Comp: $478.61k
  • Mr. Zach Simpson
    Sr. VP & Chief Accounting Officer
  • Mr. Michael D. WattenbargerMr. Michael D. Wattenbarger (Age 53)
    Exec. VP & Chief Information Officer
  • Mr. Sean P. GaffneyMr. Sean P. Gaffney (Age 44)
    Exec. VP & Chief Legal Officer
  • Mr. Roberton James Stevenson (Age 43)
    Exec. VP & Chief Human Resource Officer
  • Mr. Darby AndersonMr. Darby Anderson (Age 57)
    Exec. VP & Chief Gov. Relations Officer













ADUS Stock - Frequently Asked Questions

Should I buy or sell Addus HomeCare stock right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Addus HomeCare in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" ADUS shares.
View ADUS analyst ratings
or view top-rated stocks.

What is Addus HomeCare's stock price forecast for 2023?

4 Wall Street analysts have issued 12-month target prices for Addus HomeCare's shares. Their ADUS share price forecasts range from $105.00 to $118.00. On average, they predict the company's share price to reach $110.50 in the next year. This suggests a possible upside of 28.9% from the stock's current price.
View analysts price targets for ADUS
or view top-rated stocks among Wall Street analysts.

How have ADUS shares performed in 2023?

Addus HomeCare's stock was trading at $99.49 at the start of the year. Since then, ADUS stock has decreased by 13.8% and is now trading at $85.72.
View the best growth stocks for 2023 here
.

When is Addus HomeCare's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, October 30th 2023.
View our ADUS earnings forecast
.

How were Addus HomeCare's earnings last quarter?

Addus HomeCare Co. (NASDAQ:ADUS) announced its quarterly earnings data on Monday, July, 31st. The company reported $0.94 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.87 by $0.07. The business earned $259.98 million during the quarter, compared to analyst estimates of $255.56 million. Addus HomeCare had a net margin of 5.39% and a trailing twelve-month return on equity of 9.06%.

What ETFs hold Addus HomeCare's stock?
What is Dirk Allison's approval rating as Addus HomeCare's CEO?

91 employees have rated Addus HomeCare Chief Executive Officer Dirk Allison on Glassdoor.com. Dirk Allison has an approval rating of 51% among the company's employees. This puts Dirk Allison in the bottom 25% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Addus HomeCare own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Addus HomeCare investors own include AbbVie (ABBV), Bank of America (BAC), Bristol-Myers Squibb (BMY), Gilead Sciences (GILD), Verizon Communications (VZ), CVS Health (CVS), Pfizer (PFE), Ulta Beauty (ULTA), Cisco Systems (CSCO) and Walt Disney (DIS).

What is Addus HomeCare's stock symbol?

Addus HomeCare trades on the NASDAQ under the ticker symbol "ADUS."

Who are Addus HomeCare's major shareholders?

Addus HomeCare's stock is owned by many different institutional and retail investors. Top institutional investors include BlackRock Inc. (15.88%), Silvercrest Asset Management Group LLC (4.33%), Dimensional Fund Advisors LP (4.05%), Principal Financial Group Inc. (3.94%), State Street Corp (3.49%) and WCM Investment Management LLC (3.17%). Insiders that own company stock include Brian Poff, Darby Anderson, David W Tucker, Esteban Lopez, Laurie Manning, Mark L First, Michael D Wattenbarger, R Dirk Allison, Roberton James Stevenson, Sean Gaffney and W Bradley Bickham.
View institutional ownership trends
.

How do I buy shares of Addus HomeCare?

Shares of ADUS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Addus HomeCare's stock price today?

One share of ADUS stock can currently be purchased for approximately $85.72.

How much money does Addus HomeCare make?

Addus HomeCare (NASDAQ:ADUS) has a market capitalization of $1.39 billion and generates $951.12 million in revenue each year. The company earns $46.03 million in net income (profit) each year or $3.31 on an earnings per share basis.

How many employees does Addus HomeCare have?

The company employs 33,182 workers across the globe.

How can I contact Addus HomeCare?

Addus HomeCare's mailing address is 6801 GAYLORD PARKWAY, FRISCO TX, 75034. The official website for the company is www.addus.com. The company can be reached via phone at (469) 535-8200, via email at investorrelations@addus.com, or via fax at 630-487-2707.

This page (NASDAQ:ADUS) was last updated on 9/23/2023 by MarketBeat.com Staff

My Account -